Theriva Biologics, Inc.
TOVXTheriva Biologics, Inc. (TOVX) is a biotechnology company focused on the development of targeted therapies for cancer and other diseases. The company specializes in the design and engineering of oncolytic viruses and other biologic treatments to improve safety and efficacy in cancer therapy. Based in the United States, Theriva aims to advance innovative solutions through its proprietary platforms and collaborations.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| January 10, 2008 | $0.05 | 2007-12-27 | 2007-12-31 |
Dividends Summary
- Consistent Payer: Theriva Biologics, Inc. has rewarded shareholders with 1 dividend payments over the past 0 years.
- Total Returned Value: Investors who held TOVX shares during this period received a total of $0.05 per share in dividend income.
- Latest Payout: The most recent dividend of $0.05/share was paid 6764 days ago, on January 10, 2008.
Company News
Theriva Biologics reported Phase 1 trial results for VCN-01, an oncolytic adenovirus combined with durvalumab, in immunotherapy-refractory head and neck squamous cell carcinoma patients. The study demonstrated prolonged overall survival (15.5-17.3 months depending on dosing arm) and biomarker evidence supporting VCN-01's stroma-degrading and immu...
Theriva Biologics announced upcoming presentation of additional data from the VIRAGE Phase 2b clinical trial of VCN-01 at the AACR 2026 Annual Meeting. The tumor response, biomarker, and subgroup analyses support an immune-mediated mechanism of action and demonstrate improved patient outcomes, including in patients with hepatic metastases. The co...
Small- and mid-cap stocks are gaining momentum on execution milestones and transformative deals. Interactive Strength surged 40% after acquiring Ergatta to boost revenue guidance by 50%. Kraig Biocraft Laboratories activated its 2026 production program for spider silk manufacturing. Theriva Biologics out-licensed an asset to focus on its pancreat...
Theriva Biologics announced that clinical and safety results from a Phase 1 study of VCN-01 (zabilugene almadenorepvec) for refractory retinoblastoma will be presented at the 41st Asia-Pacific Academy of Ophthalmology Congress in Hong Kong on February 7, 2026. The presentation will include preclinical data demonstrating synergistic antitumor acti...
Theriva Biologics received favorable scientific advice from the European Medicines Agency (EMA) on the design of a Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA approved the proposed trial design, sample size, and adaptive design elements. ...
